|
|
Overview
Highlights
News
Chart
Contacts
|
|
|
|
|
|
|
|
|
| | "Announced
4th Quarter net earnings for 2008 of $2.9 million, compared with a net
loss of $10.8 million for 2007."
|
| |
|
| |
|
|
|
| Approximate
Financial Snapshot as of 6/12/08 |
|
| Shares
Outstanding |
27.4M |
| 52
Wk Hi/Lo |
18.50/ 9.59
|
| Market
Cap |
$471M |
| Recent
Price |
$17.19 |
|
|
|
|
|
|
6/12/08
Cyberonics
(CYBX)

Website:
www.cyberonics.com
Pioneer
of the Vagus Nerve Stimulation
Overview
Cyberonics (Nasdaq: CYBX)
pioneered the Vagus Nerve Stimulation (VNS Therapy™) System. Founded in
1987 to design, develop and market implantable medical devices for the
treatment of epilepsy and other debilitating neurological disorders,
Cyberonics has emerged as a leader in the neuromodulation industry.
The VNS Therapy System uses a surgically
implanted medical device that delivers electrical pulsed signals to the
vagus nerve in the left side of the neck. This therapy has proven effective
in significantly reducing the number and/or intensity of seizures in many
people suffering from epilepsy and has the potential for use in the
treatment of other inadequately treated, chronic disorders.
In 1997, Cyberonics received approval from
the Food and Drug Administration (FDA) to market VNS Therapy for the
treatment of epilepsy. Since that time, more than 32,000 patients worldwide
have been implanted with the device. These patients have accumulated in
excess of 100,000 patient years of experience using this life-enhancing
therapy.
The remarkable success of VNS Therapy in the
treatment of epilepsy has served as a platform for continued innovation. In
July, 2005 , after seven years of extensive study and clinical trials, VNS
Therapy was approved by the FDA as a long-term adjunctive treatment for
treatment-resistant depression. It is also at various levels of study as a
potential treatment for other chronic disorders, including anxiety,
Alzheimer’s, bulimia, and migraine headaches.
CYBX
Investor Highlights
- CYBX announced 4th Quarter net sales of
$33.9 million, an 8% increase from $31.4 million.
- Announced 4th Quarter net earnings of $2.9
million, including $1.3 million in insurance recoveries and $0.4 million
in state tax credits, compared with a net loss of $10.8 million.
- Earnings per diluted share of $0.11 cents,
compared with a loss of $0.42 cents per share.
- International net sales increased by 32%
in fiscal 2008 to a record $26.3 million, up from the $19.9 million
reported in fiscal 2007.
Recent
News and Press Releases
Cyberonics
Reports Strong Revenue Growth and Profitability in Fiscal 2009 First Quarter
Cyberonics
Board of Directors Nominates Joseph E. Laptewicz
Cyberonics
to Present at Collins Stewart Fourth Annual Growth Conference
Cyberonics
Reports Strong Revenue Growth and Profitability in Fiscal 2008 Fourth
Quarter
Cyberonics
Announces 2008 Bank Of America Health Care Conference Presentation
For the latest Quote
and News on CYBX Click
Here.
Three
Month Chart

Contacts
Cyberonics Inc.
Cyberonics Building
100 Cyberonics Boulevard
Houston, TX 77058-2072
Phone: 281-228-7200
SEC Filings
CYBX filings with the SEC can be found here.
All Fillings are current and the Company is fully reporting.
Disclaimer
SmallCapReview.com
feature stock reports are intended to be stock ideas, NOT recommendations.
Please do your own research before investing. It is crucial that you at
least look at current SEC filings and read the latest press releases.
For continuing coverage of CYBX, please sign up for our free newsletter.
Information contained in this report was extracted from current documents
filed with the SEC, the company web site and other publicly available
sources deemed reliable. For more information see our disclaimer section, a
link of which can be found on our web site. This document contains
forward-looking statements, particularly as related to the business plans of
the Company, within the meaning of Section 27A of the Securities Act of 1933
and Sections 21E of the Securities Exchange Act of 1934, and are subject to
the safe harbor created by these sections. Actual results may differ
materially from the Company's expectations and estimates. The information
provided in this report is not intended for distribution to, or use by, any
person or entity in any jurisdiction or country where such distribution or
use would be contrary to law or regulation or which would subject us to any
registration requirement within such jurisdiction or country.
Copyright
SmallCapReview.com. All rights reserved. SmallCapReview.com is not a
Registered Broker/Dealer or Financial Advisor, nor do we hold ourselves out
to be. All materials presented on our web site and individual reports
released to the public through this web site, e-mail or any other means of
transmission are not to be regarded as investment advice and are only
for informative purposes. Before making a purchase or sale of any securities featured
on our web site or mentioned in our reports, we strongly encourage and
recommend consultation with a registered securities representative.
This is not to be construed as a solicitation or recommendation to buy or
sell securities. As with any stock, companies we select to profile involve a
degree of investment risk and volatility. Particularly Small-Caps and OTC-BB
stocks. All investors are cautioned that they may lose all or a portion of
their investment if they decide to make a purchase in any of our profiled
companies. Past performance of our profiled stocks is not indicative of
future results. The accuracy or completeness of the information on our web
site or within our reports is only as reliable as the sources they were
obtained from. The profile and opinions expressed herein are expressed
as of the date the profile is posted on site and are subject to change
without notice. No investor should assume that reliance on the views,
opinions or recommendations contained herein will produce profitable
results. SmallCapReview.com may hold
positions in securities mentioned herein, and may make purchases or sales in
such securities featured on our web site or within our reports. In order to
be in full compliance with the Securities Act of 1933, Section 17(b),
SmallCapReview.com will disclose in it's disclaimer, what, if any
compensation was received for our efforts in researching, presenting
and disseminating this information to our subscriber database and featuring
the report on the SmallCapReview.com web site. SmallCapReview.com
has not been compensated for its efforts in presenting the Cyberonics profile on its website and distributing it to its
database of subscribers. SmallCapReview.com
may decide to purchase or sell shares on a voluntary basis in the open
market before, during or after the profiling period of this report.
Information presented on our web site and within our reports contain
"forward looking statements" within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E
of the Securities Exchange Act of 1934. Any statements that express or
involve discussions with respect to predictions, expectations, beliefs,
plans, projections, objectives, goals, assumptions or future events or
performance are not statements of historical fact and may be "forward
looking statements." Forward looking statements are based on
expectations, estimates and projections at the time the statements are made
that involve a number of risks and uncertainties which could cause actual
results or events to differ materially from those presently anticipated.
Forward looking statements in this action may be identified through the use
of words such as “expects’”, “will,” “anticipates,”
“estimates, “believes,” or that by statements indicating certain
actions “may,” “could,” or “might” occur.
THE
READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE
INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SMALL CAP
SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.
We
encourage our readers to invest carefully and read the investor information
available at the web sites of the Securities and Exchange Commission (SEC)
at: http://www.sec.gov
and/or the National Association of Securities Dealers (NASD) at: http://www.nasd.com
. Readers can review all public filings by companies at the SEC's EDGAR
page. The NASD has published information on how to invest carefully at its
web site.
|